

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
February 5, 2018**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Helix BioMedix, Inc.

File No. 033-20897-D - CF#35829

Helix BioMedix, Inc. submitted an application under Rule 24b-2 requesting an extension of previous grants of confidential treatment for information it excluded from the Exhibits to Form 10-QSB filed on November 8, 2007 and Form 10-Q filed on August 5, 2010.

Based on representations by Helix BioMedix, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit	to Form	Filed on	Confidential Treatment Granted
10.24(a)	10-QSB	November 8, 2007	through December 31, 2019
10.7(b)	10-Q	August 5, 2010	through December 31, 2019

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary